395 related articles for article (PubMed ID: 31064850)
1. Upregulation of Scavenger Receptor B1 Is Required for Steroidogenic and Nonsteroidogenic Cholesterol Metabolism in Prostate Cancer.
Gordon JA; Noble JW; Midha A; Derakhshan F; Wang G; Adomat HH; Tomlinson Guns ES; Lin YY; Ren S; Collins CC; Nelson PS; Morrissey C; Wasan KM; Cox ME
Cancer Res; 2019 Jul; 79(13):3320-3331. PubMed ID: 31064850
[TBL] [Abstract][Full Text] [Related]
2. Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.
Han W; Gao S; Barrett D; Ahmed M; Han D; Macoska JA; He HH; Cai C
Oncogene; 2018 Feb; 37(6):710-721. PubMed ID: 29059155
[TBL] [Abstract][Full Text] [Related]
3. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.
Leon CG; Locke JA; Adomat HH; Etinger SL; Twiddy AL; Neumann RD; Nelson CC; Guns ES; Wasan KM
Prostate; 2010 Mar; 70(4):390-400. PubMed ID: 19866465
[TBL] [Abstract][Full Text] [Related]
4. Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis.
Hagberg Thulin M; Nilsson ME; Thulin P; Céraline J; Ohlsson C; Damber JE; Welén K
Mol Cell Endocrinol; 2016 Feb; 422():182-191. PubMed ID: 26586211
[TBL] [Abstract][Full Text] [Related]
5. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
[TBL] [Abstract][Full Text] [Related]
6. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
[TBL] [Abstract][Full Text] [Related]
7. Nuclear Receptor LRH-1 Functions to Promote Castration-Resistant Growth of Prostate Cancer via Its Promotion of Intratumoral Androgen Biosynthesis.
Xiao L; Wang Y; Xu K; Hu H; Xu Z; Wu D; Wang Z; You W; Ng CF; Yu S; Chan FL
Cancer Res; 2018 May; 78(9):2205-2218. PubMed ID: 29438990
[TBL] [Abstract][Full Text] [Related]
8. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
[TBL] [Abstract][Full Text] [Related]
9. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
10. Nuclear receptor ERRα contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis.
Xu Z; Ma T; Zhou J; Gao W; Li Y; Yu S; Wang Y; Chan FL
Theranostics; 2020; 10(9):4201-4216. PubMed ID: 32226548
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Scavenger Receptor Class B Type 1 (SR-B1) Expression and Activity as a Potential Novel Target to Disrupt Cholesterol Availability in Castration-Resistant Prostate Cancer.
Pandey M; Cuddihy G; Gordon JA; Cox ME; Wasan KM
Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575583
[TBL] [Abstract][Full Text] [Related]
12. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
[No Abstract] [Full Text] [Related]
13. BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK.
Shafran JS; Andrieu GP; Györffy B; Denis GV
Mol Cancer Res; 2019 Aug; 17(8):1627-1638. PubMed ID: 31110158
[TBL] [Abstract][Full Text] [Related]
14. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer.
Singh KB; Ji X; Singh SV
Mol Cancer Ther; 2018 Oct; 17(10):2079-2090. PubMed ID: 30030299
[TBL] [Abstract][Full Text] [Related]
16. Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells.
Yenki P; Bhasin S; Liu L; Nabavi N; Cheng CW; Tam KJ; Peacock JW; Adomat HH; Tombe T; Fazli L; Ivanova L; Dusek C; Khosravi S; Guns EST; Wang Y; Buttyan R; Gleave ME; Ong CJ
Endocr Relat Cancer; 2023 Dec; 30(12):. PubMed ID: 37800655
[TBL] [Abstract][Full Text] [Related]
17. Intracrine androgen biosynthesis in renal cell carcinoma.
Lee GT; Han CS; Kwon YS; Patel R; Modi PK; Kwon SJ; Faiena I; Patel N; Singer EA; Ahn HJ; Kim WJ; Kim IY
Br J Cancer; 2017 Mar; 116(7):937-943. PubMed ID: 28253524
[TBL] [Abstract][Full Text] [Related]
18. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.
Mostaghel EA; Marck BT; Plymate SR; Vessella RL; Balk S; Matsumoto AM; Nelson PS; Montgomery RB
Clin Cancer Res; 2011 Sep; 17(18):5913-25. PubMed ID: 21807635
[TBL] [Abstract][Full Text] [Related]
19. Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer.
Mostaghel EA; Zhang A; Hernandez S; Marck BT; Zhang X; Tamae D; Biehl HE; Tretiakova M; Bartlett J; Burns J; Dumpit R; Ang L; Matsumoto AM; Penning TM; Balk SP; Morrissey C; Corey E; True LD; Nelson PS
Clin Cancer Res; 2019 Jan; 25(1):426-439. PubMed ID: 30181386
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression.
Gowda PS; Deng JD; Mishra S; Bandyopadhyay A; Liang S; Lin S; Mahalingam D; Sun LZ
Mol Cancer Res; 2013 Nov; 11(11):1448-61. PubMed ID: 23989930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]